Loading
NASDAQHealthcareBiotechnology
Latest quote
$4.89
+$0.05 · +1.03%
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Previous close
$4.89
+$0.05 · +1.03%
Regular session · ET · Market data may be delayed.
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Day range
Current $4.89
52-week range
Current $4.89
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Sell
Trim exposure — unfavorable risk-reward
Valuation
29
Expensive
Sentiment
43
Mixed
Risk
72
High Risk
Momentum
26
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Day range
Current $4.89
52-week range
Current $4.89
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 654K USD | 1.66M USD |
| Gross profit | — | — | — | 654K USD | 1.66M USD |
| Research and development | 63.8M USD | 74.09M USD | 53.13M USD | 49.16M USD | 45.12M USD |
| Selling, general, and administrative | 45.46M USD | 31.68M USD | 15.38M USD | 12M USD | 7.17M USD |
| Operating expenses | 109.26M USD | 105.77M USD | 68.51M USD | 61.16M USD | 52.29M USD |
| Interest income | 6.13M USD | 7.56M USD | 2.87M USD | 1.33M USD | 15K USD |
| Interest expense | 206K USD | 114K USD | 205K USD | 91K USD | — |
| Depreciation and amortization | 2.08M USD | 2M USD | 1.84M USD | 1.15M USD | 13K USD |
| Operating income | −109.26M USD | −105.77M USD | −68.51M USD | −60.51M USD | −50.64M USD |
| Net income | −99.96M USD | −98.33M USD | −66.39M USD | −59.28M USD | −50.62M USD |
Company facts updated Sep 5, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
